Gilead Sciences Rating Reiterated by TheStreet (GILD)
Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reaffirmed by TheStreet in a research note issued on Friday, Analyst Ratings.Net reports.
The analysts wrote, “Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.”
Several other analysts have also recently commented on the stock. Analysts at Ameriprise Financial initiated coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note to investors on Thursday. They set a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of Gilead Sciences (NASDAQ:GILD) from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, August 6th. They now have a $73.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Gilead Sciences (NASDAQ:GILD) in a research note to investors on Monday, July 29th. They now have a $66.00 price target on the stock.
Five investment analysts have rated the stock with a hold rating and twenty-three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $67.87.
Gilead Sciences (NASDAQ:GILD) traded up 0.03% during mid-day trading on Friday, hitting $64.3361. 3,153,900 shares of the company’s stock traded hands. Gilead Sciences has a 52-week low of $32.07 and a 52-week high of $64.74. The stock has a 50-day moving average of $60.60 and a 200-day moving average of $54.18. The company has a market cap of $98.474 billion and a P/E ratio of 35.99. Gilead Sciences also was the target of some unusual options trading on Thursday. Investors bought 17,357 put options on the stock. This represents an increase of 343% compared to the average volume of 3,921 put options.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, July 25th. The company reported $0.50 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.50. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the prior year, the company posted $0.99 earnings per share. The company’s quarterly revenue was up 14.5% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $1.97 earnings per share for the current fiscal year.
In other Gilead Sciences news, EVP Norbert Bischofberger sold 90,000 shares of the stock on the open market in a transaction dated Monday, September 16th. The shares were sold at an average price of $63.11, for a total transaction of $5,679,900.00. Following the completion of the transaction, the executive vice president now directly owns 2,159,643 shares in the company. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.